Key result
G-proteins and NO/cGMP blockers represent unexplored frontiers in the pharmaceutical industry, with potential therapeutic roles in the pathophysiology of vasospasm after ischemia and reperfusion.
This review discusses the therapeutic potential of targeting G-proteins and NO/cGMP pathways in conditions such as vasospasm following global ischemia and reperfusion.
Does not support clinical use of G-protein or NO/cGMP blockers; leaves open their investigation as therapeutic targets in post-ischemic vasospasm.
Proteinas G: potencial papel terapeutico A liberacao de oxido nitrico (NO) pode ocorrer por diferentes vias envolvendo proteinas G. A proteina Gi e responsavel pela mediacao dos efeitos inibitorios dos receptores nas vias adenilato ciclase e guanilato ciclase. Um estagio inicial da maioria das respostas mediadas por receptores e a ativacao das proteinas G na membrana celular, alvo da modulacao de uma variedade de eventos intracelulares. O papel das proteinas G na fisiopatologia do vasoespasmo apos isquemia global e reperfusao [...]
No takes yet. Share an insight, caveat, or question.
Paulo Roberto Barbosa Évora (2017) conducted a review in Vasospasm after global ischemia and reperfusion. G-Proteins Agonists and NO/cGMP Blockers was evaluated. G-proteins and NO/cGMP blockers represent unexplored frontiers in the pharmaceutical industry, with potential therapeutic roles in the pathophysiology of vasospasm after ischemia and reperfusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: